Shana Kelley

that we could treat a tumor with them.

So this is just kind of how the road of serendipity usually goes for us.

You know, unmet need, technology platform, always takes a while to find that kind of really compelling application, but we work and work and work till we

find something, and then we partner, we spin companies out.

That company in particular that is taking the blood-borne tumor-reactive lymphocytes is taking that approach towards the clinic.

And that's really my passion is developing these things and then trying to move them along so that they can have a positive impact on patients.

And we're just kind of agnostic about that.

All that really matters is the impact.

Yeah, that again, it was just another unsolved problem, something that we spotted that we thought was really interesting.

And the problem that we're trying to tackle there is how do you get a molecule into a cell, but then into the mitochondria of the cell?

The mitochondria are doing all these really interesting things.

Those are the energy producers, obviously, but they have a lot of other signaling capabilities.

There's DNA in mitochondria, which we don't completely understand what it does or doesn't do.

So we just started developing chemical probes that could get there.

And then we could ask a lot of questions about

on how all of the machinery and mitochondria works together.

And it's been really fascinating.

No startup there yet, but it's been a really interesting project.

Yeah, I think, you know, being interdisciplinary really helps.

You have to bring different things together.